Therapy Clinical Trial
Official title:
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, thus
alternatives must be sought to improve eradication. Aim: To determine CYP2C19 genetic
polymorphism effect on H. pylori eradication.
Methods: A randomized single blinded clinical trial including 133 patients was carried-out.
H. pylori infection was confirmed by histology and microbiological test. Antibiotic
susceptibility to amoxicillin and clarithromycin was performed to avoid confusion bias in
analysis results. CYP2C19 polymorphism "asterisk" *1, "asterisk"*2 and "asterisk" *3 was
analyzed by Real time PCR (Roche ®), and nested PCR for CYP2C19 "asterisk" *17 polymorphism.
Participants were randomized into two groups for different H. pylori therapies, one with
standard omeprazole doses and another with omeprazole doses depending on CYP2C19
polymorphism. H. pylori eradicating was verified by stool antigen testing (Meridian ®). The
general results was analysis by statistical computer program and the effectiveness of each
therapy was analyzed by intention to treat (ITT) and by protocol (PP).
The study allowed to know the prevalence of the main polymorphisms of CYP2C19 in
Bogotá-Colombia, also allowed to know the effectivenesses of the two therapies evaluated for
H. pylori infection. Additionally, the importance of personalized medicine in H. pylori
eradication therapy was known.
Introduction:
H. pylori has been declared and ratified as carcinogen I by the World health organization
(WHO) International agency for research on cancer (IARC). Globally first line therapy
eradication treatment recommended for H. pylori, combines a proton-pump inhibitor (PPI) with
two antibiotics (amoxicillin and clarithromycin or metronidazole). However, today
effectiveness of this therapy is less than 75% "percentage", due mainly to H. pylori
antibiotic resistance. Other factors involved in therapeutic failure are treatment adherence
and host genetic factors that may affect medication pharmacokinetics, specifically PPI
pharmacokinetics PPI play an essential role in eradication therapies, it suppresses deeply
acid secretion, thus increasing hydrogen ion potential (pH) above 6.0. This allows H. pylori
to replicate more actively than when stomach pH is less than 6.0, therefore improves
antibiotic activity promoting greater antimicrobial agent stability and antibiotic
concentration in stomach. PPIs action depends on its metabolism by cytochrome P450 (CYP)
enzymes.Recent studies have showed that CYP2C19 genotype can affect PPIs ability to suppress
acid secretion in the stomach, as has been observed for omeprazole. Omeprazole is metabolized
by CYP2C19 (90%"percentage") and by CYP3A4 (10%"percentage"). CYP2C19 gene has 21
polymorphisms, three of which play an important role in PPIs metabolism. Thus, depending on
polymorphism they are designated as early metabolizers (EM) ("asterisk"*1/"asterisk"*1),
intermediate metabolizers (IM) ("asterisk"*1/"asterisk"*X) and poor metabolizers (PM)
("asterisk"*X/"asterisk"*X). Where "asterisk"*1 allele is the wild type allele ("Wild type")
and "asterisk"*X correspond to mutated allele. Patients with genotype CYP2C19
"asterisk"*1/"asterisk"*2 o"asterisk" *1/"asterisk"*3 are IM and those with genotype CYP2C19
"asterisk"*2/"asterisk"*2 or CYP2C19 "asterisk"*3/"asterisk"*3 are PM. The presence of
CYP2C19 "asterisk"*2 and CYP2C19 "asterisk"*3 polymorphisms predict the individual
metabolizer phenotype. In 2006 the CYP2C19"asterisk"*17 allele was found, whose function is
clinically important because heterozygotes, with CYP2C19"asterisk"*1/"asterisk"*17 forms are
simply considered ultra-fast metabolizers by other authors. The clinical implication of this
latter polymorphism relies on the following: if PPIs are quickly metabolized, standard PPIs
dose fails to adequately suppress acid secretion, and H. pylori eradication therapy will be
less effective if the microorganism is sensitive to antibiotics. A recent work in Colombia to
eradicate H. pylori, using triple therapy with clarithromycin or levofloxacin combined with
amoxicillin, reported that although the organism was sensitive to these antibiotics, there
was variability with the achieved eradication. These results may suggest the possibility that
additional factors, different from antimicrobial resistance, can influence the treatment
effectiveness in our population.
General Methods:
The aim of present was to determine CYP2C19 genetic polymorphism influence on H.pylori
eradication. For this purpose a randomized single blinded clinical trial was done. It was
conducted from 2012 to 2015 in Bogotá, Colombia. The study was performed in accordance with
Good Clinical Practice guidelines and ethical principles of the Declaration of Helsinki.
Ethics Committee of the participating institutions approved the study protocol, where all
participants signed written informed consent.
After obtaining informed consent, 356 patients were invited to participate in the study. All
enrolled participants underwent initial endoscopy, carried-out at the upper endoscopy
service, clinical center from Bogotá, D.C., Colombia to obtain gastric biopsy for histology,
microbiological and genotypic test. However, due to the strict inclusion and exclusion
criteria proposed, of the 356 participants, only 133 were included in the study.
All participants in the study underwent endoscopy of upper digestive tract under aseptic
conditions, with a minimum of six hours of fasting. During the endoscopy five biopsies were
taken from the antrum and four biopsies from the body for histopathology, microbiology and
molecular analysis. For histopathological analysis, the biopsy samples were sent to pathology
in separate properly marked containers. For microbiological and molecular analyses three
antral and three body of the stomach biopsies were collected and used as follows: one biopsy
from antrum for rapid urease test, two biopsies (antrum and one from the body of the stomach)
for H. pylori culture and susceptibility test. Culturing was carried out only when one or
both additional tests were positive for H. pylori. If the culture was negative, but any other
tests were positive, microorganism detection was confirmed by molecular biology analysis
(ureA gene detection H. pylori). It was considered a participant was infected with H. pylori
when two or more tests were positive. Another biopsy was used for DNA extraction and
subsequent analysis of CYP2C19 genetic polymorphism.
Culture was performed from biopsies of participants whose rapid urease test and histology
were positive, from a biopsy of antrum and body of the stomach on Brucella agar (BD) enriched
with 7% "percentage" v/v horse blood, Isovitalex (BD) and Helicobacter Pylori Selective
Supplement (Dent) (Oxoid). Following, the samples were incubated at 37°C with 11%
"percentage"carbon dioxide (CO2) for 3 to 5 days. Antibiotic susceptibility test from pure
colonies was carried-out by agar dilution (gold standard method) according to the Clinical
and Laboratory Standards Institute (CLSI) to determine amoxicillin and clarithromycin minimum
inhibitory concentration (MIC). In addition, CYP2C19 polymorphism
"asterisk"*1,"asterisk"*2,"asterisk"*3 and "asterisk"*17 were identified for all 133 patients
included in this study. For this propose DNA was obtained from gastric biopsies by DNA
Isolation from Human Samples from commercial Kit (QIAGEN), and then the identification of the
respective polymorphisms was done.
CYP2C19 "asterisk"*1,"asterisk"*2,"asterisk"*3 polymorphisms were determined by real-time
polymerase chain reaction (RT-PCR) using Modular Assays kit for human CYP2C19"asterisk"*2 and
CYP2C19"asterisk"*3 (Roche), according to manufacturer's instructions. And nested PCR and
Restriction Fragment Length Polymorphism (RFLP) was done for determination of allele
"asterisk"*17 according with Baldwin et al. report.
Due to the study compared two types of therapies, the 133 patients were randomized for
received the treatments into two groups by a computer program. Group one or conventional
group and group 2 or personalized group. Both groups received amoxicillin and clarithromycin
but first group received standard doses of omeprazole and in the second group omeprazole
doses was adjusting according to the CYP2C19 polymorphism of each participant.
After performing microbiological and molecular testing, the participants were allocated to a
treatment regimen according to a randomized crossover sequence, provided by a
computer-generated randomization list. Participants were contacted by telephone for assigned
an appointment for treatment delivery according to the assigned group.
All participants were given detailed information about the adverse effects that could occur
with the different medications. Verification of possible adverse effects was performed
telephonically using a validated and pre-coded questionnaire that included the following
symptoms: diarrhea, metallic taste, nausea, bloated feeling, loss of appetite, vomiting,
abdominal pain, constipation, and rash. The intensity of each symptom was graded from zero to
three: 0: absent, 3: severe, using a Likert scale. Finally H. pylori eradication was verified
8 weeks post treatment by antigen test (Meridian®). For this test, each participants was
requested a stool sample. The test was carried-out according to manufacturer's indications.
For the analysis of results, a database of the participants in excel and in spss was
generated. These databases included general characteristics of each participant, result of
each of the microbiology tests, molecular biology. Descriptive statistics and analysis of the
effectiveness of the treatments used were carried out.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05788861 -
Invasive Group A Streptococcal Infection
|
||
Completed |
NCT03712748 -
Online Imaginal Exposure
|
N/A | |
Completed |
NCT01031667 -
Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)
|
Phase 4 | |
Recruiting |
NCT00226408 -
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
|
Phase 3 | |
Completed |
NCT05104957 -
Evaluation of the Kinesiology Taping Effectiveness in the Treatment of Lumbar Spine Pain
|
N/A | |
Recruiting |
NCT06137053 -
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
|
||
Completed |
NCT01023126 -
Obesity and Psychotherapy as an Alternative to Treatment
|
N/A | |
Not yet recruiting |
NCT06413407 -
Tai Chi Exercise and Receptive Music Therapy for the Elderly
|
N/A | |
Recruiting |
NCT06040515 -
Probiotic After Acute Colonic Diverticulitis
|
||
Recruiting |
NCT05340738 -
AI-Based Fidelity Feedback to Enhance CBT
|
N/A | |
Active, not recruiting |
NCT02455609 -
Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05261503 -
Investigation of the Effectiveness of Environmental Enrichment-Based Intervention in Preterm Infants
|
N/A | |
Completed |
NCT04926311 -
Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder
|
||
Recruiting |
NCT03721783 -
Infant and Child European Cryoablation Project ICECaP
|
||
Recruiting |
NCT03283839 -
Consequences of Temporomandibular Disorder on Balance Control
|
N/A | |
Recruiting |
NCT05901558 -
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
|
N/A | |
Completed |
NCT03177863 -
Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age
|
N/A | |
Recruiting |
NCT06146972 -
Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis
|
Phase 4 | |
Recruiting |
NCT03161249 -
Psychoeducative Treatment of FEP With Mobile Training
|
N/A | |
Recruiting |
NCT04490317 -
CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
|